GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » Quick Ratio

Zydus Lifesciences (BOM:532321) Quick Ratio : 0.00 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Zydus Lifesciences's quick ratio for the quarter that ended in Dec. 2023 was 0.00.

Zydus Lifesciences has a quick ratio of 0.00. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Zydus Lifesciences's Quick Ratio or its related term are showing as below:

BOM:532321' s Quick Ratio Range Over the Past 10 Years
Min: 0.7   Med: 0.88   Max: 1.52
Current: 1.52

During the past 13 years, Zydus Lifesciences's highest Quick Ratio was 1.52. The lowest was 0.70. And the median was 0.88.

BOM:532321's Quick Ratio is ranked better than
56.56% of 1075 companies
in the Drug Manufacturers industry
Industry Median: 1.34 vs BOM:532321: 1.52

Zydus Lifesciences Quick Ratio Historical Data

The historical data trend for Zydus Lifesciences's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zydus Lifesciences Quick Ratio Chart

Zydus Lifesciences Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.79 0.72 0.70 1.09 1.19

Zydus Lifesciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.19 - 1.52 -

Competitive Comparison of Zydus Lifesciences's Quick Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Zydus Lifesciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zydus Lifesciences's Quick Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zydus Lifesciences's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Zydus Lifesciences's Quick Ratio falls into.



Zydus Lifesciences Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Zydus Lifesciences's Quick Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Quick Ratio (A: Mar. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(100164-34133)/55307
=1.19

Zydus Lifesciences's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0-0)/0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zydus Lifesciences  (BOM:532321) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Zydus Lifesciences Quick Ratio Related Terms

Thank you for viewing the detailed overview of Zydus Lifesciences's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zydus Lifesciences (BOM:532321) Business Description

Traded in Other Exchanges
Address
Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. The product portfolio of the group includes Active Pharmaceutical Ingredients, human formulations, Health and wellness, and Animal health and veterinary products. Its product brands include Aten, Falcigo, Nucoxia, Levoday, Metscore and Arzep among others. It has two segments Pharmaceuticals and Consumer Products. It generates majority of its revenue from the Pharmaceutical segment.

Zydus Lifesciences (BOM:532321) Headlines

No Headlines